PDCD1 and hemophagocytic syndrome: Our colleague Liu P et al (9) first tested the PD-1 inhibitor nivolumab in 7 R/R EBV-HLH patients, and 5/7 patients achieved complete clinical remission, with a median follow-up of 16 months.